Clinical trial
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
NCT00194649 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00194649 |
|---|---|
| Title | Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2) |
| Official title | Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study |
| Acronym | MIG-2 |
| Lead sponsor | University of Washington, Other |
| Collaborators | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Contraception |
| Intervention type | Drug |
| Interventions | Miglustat (Zavesca) |
| Enrollment | 8 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 19, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: